Press release
Myasthenia Gravis Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, and Drug Development Insights
Curious about the latest updates in the Myasthenia Gravis Pipeline? Click here to explore the therapies and trials making headlines @ Myasthenia Gravis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myasthenia Gravis Pipeline Report
* On 03 October 2025, argenx announced a study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.
* On 02 October 2025, Novartis Pharmaceuticals conducted a study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
* DelveInsight's Myasthenia Gravis Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myasthenia Gravis treatment.
* The leading Myasthenia Gravis Companies such as Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
* Promising Myasthenia Gravis Therapies such as NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
Want to know which companies are leading innovation in Myasthenia Gravis? Dive into the full pipeline insights @ Myasthenia Gravis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myasthenia Gravis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Myasthenia Gravis Pipeline Report also highlights the unmet needs with respect to the Myasthenia Gravis.
Myasthenia Gravis Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body's immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.
Myasthenia Gravis Emerging Drugs
* HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
Batoclimab (HBM9161) is a novel, fully human anti-FcRn mAb blocking FcRn-IgG interactions and accelerating the degradation of autoantibodies. The product has the potential to address a variety of pathogenic IgG-mediated autoimmune diseases. Batoclimab is being evaluated for the treatment of patients with severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG), including generalized myasthenia gravis (gMG), thyroid eye disease (TED), neuromyelitis optica spectrum disorder (NMOSD) and immune thrombocytopenic purpura (ITP). Phase II study in generalized myasthenia gravis showed that batoclimab can quickly and significantly alleviate patients' symptoms and improve quality of life. Completed studies demonstrated that batoclimab is well tolerated and can rapidly reduce total IgG in a wide array of pathogenic IgG-mediated autoimmune diseases. Currently, the drug is in Preregistration stage of its development for the treatment of Myasthenia Gravis.
* KYV-101: Kyverna Therapeutics
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, systemic sclerosis, and myasthenia gravis are in preparation. Currently, the drug is in Phase II stage of its development for the treatment of Myasthenia Gravis.
* CABA-201: Cabaletta Bio
CABA-201 is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain. CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, which may enable an "immune system reset" with the potential for durable remission off therapy in patients with autoimmune diseases. To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions including systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc) and generalized myasthenia gravis (gMG). Cabaletta is conducting four RESET Trademark Phase I/II clinical trials with a total of nine cohorts that can advance simultaneously, employing a similar parallel cohort design and starting dose of 1 x 106 cells/kg without a dose escalation requirement. Currently, the drug is in Phase I/II stage of its development for the treatment of Myasthenia Gravis.
If you're tracking ongoing Myasthenia Gravis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Myasthenia Gravis Treatment Drugs [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Myasthenia Gravis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.
* Myasthenia Gravis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.
Myasthenia Gravis Companies
Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
Myasthenia Gravis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Myasthenia Gravis Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Myasthenia Gravis Pipeline Report covers it all - check it out now @ Myasthenia Gravis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myasthenia Gravis Pipeline Report
* Coverage- Global
* Myasthenia Gravis Companies- Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals , and others.
* Myasthenia Gravis Therapies- NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
* Myasthenia Gravis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myasthenia Gravis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Myasthenia Gravis Treatment landscape in this detailed analysis @ Myasthenia Gravis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Myasthenia Gravis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myasthenia Gravis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KYV-101: Kyverna Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CABA-201: Cabaletta Bio
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Myasthenia Gravis Key Companies
* Myasthenia Gravis Key Products
* Myasthenia Gravis- Unmet Needs
* Myasthenia Gravis- Market Drivers and Barriers
* Myasthenia Gravis- Future Perspectives and Conclusion
* Myasthenia Gravis Analyst Views
* Myasthenia Gravis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myasthenia-gravis-pipeline-drugs-report-2025-emerging-therapies-clinical-trials-and-drug-development-insights]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myasthenia Gravis Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, and Drug Development Insights here
News-ID: 4210441 • Views: …
More Releases from ABNewswire
Smoking Cessation Pipeline Drugs Report 2025: Drug Candidates, Emerging Therapie …
DelveInsight's, "Smoking Cessation Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the Smoking Cessation Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Smoking Cessation Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Western Pennsylvania Car Accident Attorneys from LGKG Details Evidence-Driven St …
New Castle, Pennsylvania - Western Pennsylvania car accident attorneys from Luxenberg Garbett Kelly & George P.C. (https://www.lgkg.com/proving-liability-gathering-evidence-pennsylvania-car-accident-case) outline a comprehensive, evidence-driven approach to establishing fault in Pennsylvania motor vehicle collisions. Drawing on decades of courtroom advocacy across Western Pennsylvania, Kelly highlights how timely documentation, digital data, and coordinated investigation can position injured parties for fair case outcomes while allowing medical recovery to remain the priority.
In explaining the approach, the Western…
San Antonio Divorce and Family Lawyer Linda Leeser Shares Guidance on the Disadv …
San Antonio, Texas - Family Matters Law Firm PLLC (https://myfamilymatterslaw.com/disadvantages-of-filing-for-divorce-first/) announces that San Antonio divorce and family lawyer Linda Leeser is sharing practical guidance for residents weighing whether to file for divorce first in Texas. Drawing on current Texas procedures, the overview explains how initiating a case can affect legal strategy, timelines, costs, and family dynamics while underscoring options available to protect children and finances during the process.
In the guidance,…
Illinois Divorce Lawyer Russell D. Knight Clarifies The Role Of "True Up" Clause …
Chicago, Illinois - Russell D. Knight of the Law Office of Russell D. Knight (https://rdklegal.com/what-is-a-true-up-in-an-illinois-divorce) provides a clear explanation of how a "true up" clause functions within Illinois divorce agreements, addressing recurring income fluctuations and their impact on child support and maintenance. The guidance centers on the legal framework of Illinois support statutes while highlighting how parties may contractually adopt yearly reconciliation provisions. As an Illinois Divorce lawyer, Knight outlines…
More Releases for Myasthenia
Myasthenia Gravis (MG) Treatment Market: Insights and Trends
The Global Myasthenia Gravis (MG) Treatment Market is experiencing notable growth, driven by increasing awareness of the disease and advancements in treatment options. Myasthenia Gravis is a chronic autoimmune disorder that leads to varying degrees of muscle weakness, and effective management is crucial for improving patient quality of life.
With ongoing research and development in treatment modalities, the market is poised for significant expansion over the coming years.
Market Size and Growth:
The…
Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/
Medication Segment to Dominate the Myasthenia…
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC @…
